Fibrilación auricular en el anciano

Hanon, 2013, Consensus d’experts de la Société française de gériatrie et gérontologie et de la Société française de cardiologie, sur la prise en charge de la fibrillation atriale du sujet âgé, Geriatr Psychol Neuropsychiatr Vieil, 11, 117 Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278 Camm, 2012, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, 33, 2719, 10.1093/eurheartj/ehs253 Nimmo, 2013, Management of atrial fibrillation in chronic kidney disease: double trouble, Am Heart J, 166, 230, 10.1016/j.ahj.2013.05.010 Odutayo, 2016, Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis, Br Med J, 354, i4482, 10.1136/bmj.i4482 Duron, 2010, Atrial fibrillation and cognitive function, Psychol Neuropsychiatr Vieil, 8, 209 Singh-Manoux, 2017, Atrial fibrillation as a risk factor for cognitive decline and dementia, Eur Heart J, 38, 2612, 10.1093/eurheartj/ehx208 Diener, 2017, Does atrial fibrillation lead to cognitive decline and dementia?, Eur Heart J, 38, 2619, 10.1093/eurheartj/ehx320 Lip, 2011, Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis, Thromb Haemost, 106, 997, 10.1160/TH11-10-0690 Lip, 2011, J Am Coll Cardiol, 57, 173, 10.1016/j.jacc.2010.09.024 Wyse, 2002, A comparison of rate control and rhythm control in patients with atrial fibrillation, N Engl J Med, 347, 1825, 10.1056/NEJMoa021328 Bassand, 2012, Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents, Europace, 14, 312, 10.1093/europace/eur263 Heidbuchel, 2015, Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation, Europace, 17, 1467, 10.1093/europace/euv309 January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, Circulation, 130, e199 January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society, Circulation, 130, 2071, 10.1161/CIR.0000000000000040 Potpara, 2017, Decision-making in clinical practice: oral anticoagulant therapy in patients with non-valvular atrial fibrillation and a single additional stroke risk factor, Adv Ther, 34, 357, 10.1007/s12325-016-0458-7 Singer, 2009, The net clinical benefit of warfarin anticoagulation in atrial fibrillation, Ann Intern Med, 151, 297, 10.7326/0003-4819-151-5-200909010-00003 Hohnloser, 2007, Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy, J Am Coll Cardiol, 50, 2156, 10.1016/j.jacc.2007.07.076 Taillandier, 2014, Prognosis in patients hospitalized with permanent and nonpermanent atrial fibrillation in heart failure, Am J Cardiol, 113, 1189, 10.1016/j.amjcard.2013.12.024 Nieuwlaat, 2008, Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?, Eur Heart J, 29, 915, 10.1093/eurheartj/ehn101 Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 Gage, 2006, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF), Am Heart J, 151, 713, 10.1016/j.ahj.2005.04.017 Donze, 2012, Risk of falls and major bleeds in patients on oral anticoagulation therapy, Am J Med, 125, 773, 10.1016/j.amjmed.2012.01.033 Gage, 2005, Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall, Am J Med, 118, 612, 10.1016/j.amjmed.2005.02.022 Capodanno, 2010, Antithrombotic therapy in the elderly, J Am Coll Cardiol, 56, 1683, 10.1016/j.jacc.2010.04.063 Andreotti, 2015, Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis, Eur Heart J, 36, 3238 Ruff, 2016, North American Thrombosis Forum, AF Action Initiative Consensus Document, Am J Med, 129, S1, 10.1016/j.amjmed.2016.02.001 Singer, 2009, Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation: the ATRIA study, Circ Cardiovasc Qual Outcomes, 2, 297, 10.1161/CIRCOUTCOMES.108.830232 Hylek, 1996, An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation, N Engl J Med, 335, 540, 10.1056/NEJM199608223350802 Gouin-Thibault, 2010, Improving anticoagulation control in hospitalized elderly patients on warfarin, J Am Geriatr Soc, 58, 242, 10.1111/j.1532-5415.2009.02675.x Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Diener, 2017, Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2, Eur Heart J, 38, 852 Département des études en santé publique CNdAMdTSC. Étude « en vie réelle » du bénéfice/risque à court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients débutant un traitement et non précédemment traités par des antivitamines K. Étude NACORA-BR du projet NACORA (nouveaux anticoagulants oraux et risques associés) 2014. Larsen, 2016, Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, Br Med J, 353, i3189, 10.1136/bmj.i3189 Kirchhof, 2016, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Europace, 18, 1609, 10.1093/europace/euw295 Macle, 2016, 2016 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation, Can J Cardiol, 32, 1170, 10.1016/j.cjca.2016.07.591 Anderson, 2013, Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 61, 1935, 10.1016/j.jacc.2013.02.001 Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337